Is fetuin-A/α2-heremans-schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease?

American Journal of Nephrology

Volumn 28, Issue 4, 2008, Pages 669-676

  Axelsson, Jonas ^a,d   Wang, Xin ^a,b   Ketteler, Markus ^c   Qureshi, Abdul Rashid ^a   Heimbürger, Olof ^a   Bárány, Peter ^a   Lindholm, Bengt ^a   Nordfors, Louise ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b PEKING UNIVERSITY   (China)

^c KLINIKUM COBURG   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic kidney disease; Dyslipidemia; Insulin resistance; Obesity

Indexed keywords

FAT; FETUIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN RECEPTOR; PROTEIN TYROSINE KINASE; TRIACYLGLYCEROL; ALPHA FETOPROTEIN; ALPHA2HS GLYCOPROTEIN; PLASMA PROTEIN;

ADULT; ARTICLE; ATHEROGENESIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOSE TISSUE; BLOOD; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; GENETIC POLYMORPHISM; GENETICS; HISTOLOGY; MIDDLE AGED;

ADIPOSE TISSUE; ALPHA-FETOPROTEINS; BLOOD PROTEINS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC;

EID: 45149098702     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000121358     Document Type: Article

References (32)

1. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, et al: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-833.
2. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, et al: Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383-2392.
3. Schafer C, Heiss A, Schwarz A, Westenfeld R, et al: The serum protein alpha-2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-366.
4. Osawa M, Tian W, Horiuchi H, Kaneko M, et al: Association of alpha-2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet 2005;116:146-151.
5. Heiss A, DuChesne A, Denecke B, et al: Structural basis of calcification inhibition by alpha-2HS-glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003;278:13333-13341.
6. Kramer H, Toto R, Peshock R, Cooper R, et al: Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2005;16:507-513.
7. Mehrotra R, Westenfeld R, Christenson P, Budoff M, et al: Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005;67:1070-1077.
8. Mathews ST, Chellam N, Srinivas PR, Cintron VJ, et al: Alpha-2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol 2000;164:87-98.
9. Ix JH, Shlipak MG, Brandenburg VM, Ali S, et al: Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006;113:1760-1767.
10. Stefan N, Hennige AM, Staiger H, Machann J, et al: Alpha-2-Heremans- Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006;29:853-857.
11. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, et al: Improved insulin sensitivity and resistance to weight gain in mice null for the AHSG gene. Diabetes 2002;51:2450-2458.
12. Lavebratt C, Dungner E, Hoffstedt J: Polymorphism of the AHSG gene is associated with increased adipocyte beta-2-adrenoceptor function. J Lipid Res 2005;46:2278-2281.
13. Lavebratt C, Wahlqvist S, Nordfors L, Hoffstedt J, et al: AHSG gene variant is associated with leanness among Swedish men. Hum Genet 2005;117:54-60.
14. International Diabetes Federation (IDF): The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, IDF, 2005.
15. Beddhu S, Kimmel PL, Ramkumar N, Cheung AK: Associations of metabolic syndrome with inflammation in CKD: results from the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2005;46:577-586.
16. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
17. World Health Organization (WHO): Definition, Diagnosis and Classification of Diabetes mellitus and Its Complications. 1. Diagnosis and Classification of Diabetes Mellitus. Geneva, WHO 1999.
18. Kerr PG, Strauss BJG, Atkins RC: Assessment of the nutritional state of dialysis patients. Blood Purif 1996;14:382-387.
19. Shapiro SS, Wilk MB: An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611.
20. Cintron VJ, Ko MS, Chi KD, Gross JP, et al: Genetic mapping and functional studies of a natural inhibitor of the insulin receptor tyrosine kinase: the mouse ortholog of human alpha-2-HS glycoprotein. Int J Exp Diabetes Res 2001;1:249-263.
21. Siddiq A, Lepretre F, Hercberg S, Froguel P, et al: A synonymous coding polymorphism in the alpha-2-Heremans-Schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes 2005;54:2477-2481.
22. Schafer C, Heiss A, Schwarz A, Westenfeld R, et al: The serum protein alpha-2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-366.
23. Wang AY, Woo J, Lam CW, Wang M, et al: Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005;20:1676-1685.
24. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, et al: Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007;72:202-207.
25. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, et al: Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005;81:543-554.
26. Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, et al: Serum alpha-2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993;7:1445-1455.
27. Dahlman I, Eriksson P, Kaaman M, Jiao H, et al: Alpha-2-Heremans-Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action. Diabetologia 2004;47:1974-1979.
28. Daveau M, Christian D, Julen N, Hiron M, et al: The synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 1988;241:191-194.
29. Daveau M, Davrinche C, Djelassi N, Lemetayer J, et al: Partial hepatectomy and mediators of inflammation decrease the expression of liver alpha-2-HS glycoprotein gene in rats. FEBS Lett 1990;273:79-81.
30. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, et al: Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006;21:1293-1299.
31. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, et al: Fetuin-A and kidney function in persons with coronary artery disease - data from the heart and soul study. Nephrol Dial Transplant 2006;21:2144-2151.
32. Keith DS, Nichols GA, Gullion CM, Brown JB, et al: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-663.